Pan-Cancer Analysis of CCNB2 Expression and Its Implications for Prognosis in Lung Adenocarcinoma
Brazilian Journal of Oncology · 26.06.2026 · 22 (CP)
DOI: 10.1055/s-0046-1825397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 26.06.2026. Verfasst von Eduarda Severo Alvarenga und 10 weiteren Autor:innen.
Abstract (Originalsprache)
All articles of this category (opens in new window) Address for correspondence Eduarda Severo Alvarenga (eduardasevero@alu.ufc.br)
Introduction
CCNB2 is a gene that encodes cyclin B2, a regulatory protein involved in cell cycle control, particularly in the G2/M transition. Its expression is tightly regulated under physiological conditions, as dysregulation may lead to abnormal cell proliferation and contribute to tumor development. In lung adenocarcinoma (LUAD), studies have shown significant overexpression of CCNB2 gene compared to normal lung tissue. This increased expression is associated with greater tumor aggressiveness and reduced overall survival, highlighting CCNB2 as a potential prognostic biomarker and therapeutic target .
Objective
This study aims to perform a comprehensive analysis of CCNB2 expression across multiple cancer types, with a focus on LUAD, to assess its association with patient prognosis and its potential as a molecular biomarker and therapeutic target .
Methods
An in silico analysis was conducted using GEPIA2 (Gene Expression Profiling Interactive Analysis), which integrates expression data from TCGA (The Cancer Genome Atlas) and GTEx (Genotype-Tissue Expression). CCNB2 expression was compared between tumor and normal tissues across 33 cancer types (pan-cancer analysis), identifying tumors with significantly increased expression. Overall survival (OS) was also evaluated in the pan-cancer context and specifically in LUAD. Patients were stratified into high and low expression groups based on the median CCNB2 level. Survival analysis included ~9,500 samples, with 478 from LUAD. Kaplan–Meier curves and log-rank tests were applied, with significance set at p < 0.05 .
Results
CCNB2 was significantly overexpressed in several cancers, including Bladder Urothelial Carcinoma (BLCA), Breast Invasive Carcinoma (BRCA), Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC), Liver Hepatocellular Carcinoma (LIHC), Ovarian Serous Cystadenocarcinoma (OV) and LUAD. Expression was consistently higher in tumors than in normal tissues, reinforcing its potential role in lung tumorigenesis. OS analysis showed worse prognosis in high CCNB2 expression groups, both pan-cancer (HR = 1.8; p < 0.0001) and in LUAD (HR = 1.7; p = 0.00079) .
Conclusion
CCNB2 is significantly overexpressed in multiple cancers, including LUAD, and is associated with poor clinical outcomes. These findings support its role as a negative prognostic biomarker and potential therapeutic target, warranting further functional validation in lung cancer. Publication History Article published online: 26 June 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil Bibliographical Record Eduarda Severo Alvarenga, João Luiz Lima Pinheiro, Gabriel Maciel Almeida, Abel Caminha Barreto Neto, Letícia Benevides Nunes Benevides, Valbert Oliveira Costa Filho, Carlos Alberto Barbosa Neto, Fabrícia Cardoso Marques, Maria Eduarda Medeiros Nunes, Júlia Matos Dubanhevitz, Markus Andret Cavalcante Gifoni. Pan-Cancer Analysis of CCNB2 Expression and Its Implications for Prognosis in Lung Adenocarcinoma. Brazilian Journal of Oncology 2026; 22. DOI: 10.1055/s-0046-1825397
Zitieren
APA
Alvarenga, E. S., Pinheiro, J. L. L., Almeida, G. M., Neto, A. C. B., Benevides, L. B. N., Filho, V. O. C., Neto, C. A. B., Marques, F. C., Nunes, M. E. M., Dubanhevitz, J. M., & Gifoni, M. A. C. (2026). Pan-Cancer Analysis of CCNB2 Expression and Its Implications for Prognosis in Lung Adenocarcinoma. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0046-1825397
Vancouver
Alvarenga ES, Pinheiro JLL, Almeida GM, Neto ACB, Benevides LBN, Filho VOC, et al. Pan-Cancer Analysis of CCNB2 Expression and Its Implications for Prognosis in Lung Adenocarcinoma. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0046-1825397
BibTeX
@article{Alvarenga2026,
author = {Alvarenga, Eduarda Severo and Pinheiro, João Luiz Lima and Almeida, Gabriel Maciel and Neto, Abel Caminha Barreto and Benevides, Letícia Benevides Nunes and Filho, Valbert Oliveira Costa and Neto, Carlos Alberto Barbosa and Marques, Fabrícia Cardoso and Nunes, Maria Eduarda Medeiros and Dubanhevitz, Júlia Matos and Gifoni, Markus Andret Cavalcante},
title = {Pan-Cancer Analysis of CCNB2 Expression and Its Implications for Prognosis in Lung Adenocarcinoma},
journal = {Brazilian Journal of Oncology},
year = {2026},
volume = {22},
number = {CP},
doi = {10.1055/s-0046-1825397}
}
EUVIMED